MAPT and Alzheimer disease: Thus, evidence suggests that CSF p-tau is a stronger determinant of progression rate along AD continuum than CSF Aβ, consistent with previous reports showing that tau-mediated neurodegeneration mechanisms result in heterogeneous AD progression [9, 70].